We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The lawyer for a Northern Kentucky man who blames his 2003 heart attack on the painkiller Vioxx told a jury that Merck & Co. "lost sight of telling the truth and that patient safety has to come first at all times."
Biopure Corp. won't have to pay penalties to settle allegations it touted the prospects for a synthetic blood product without disclosing that drug regulators had concerns about the product's safety, the Securities and Exchange Commission said Tuesday.
Oscient Pharmaceuticals has announced the results of a meeting of the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee.
The widely used pain reliever diclofenac poses the same cardiovascular risk as the withdrawn drug Vioxx and should not be used by people with heart disease or high blood pressure, researchers reported Tuesday.
Adolor's stock took a major hit last week after the company and GlaxoSmithKline announced data showing that their new drug alvimopan, designed to treat opioid-induced bowel dysfunction (OBD), was ineffective in two of three clinical trials.
The U.S. International Trade Commission (ITC) has decided not to review a decision made earlier this year that Roche's importation and use of its experimental anemia drug Mircera in the U.S. did not violate Amgen's patents on its anemia drug Epogen.
Repercussions from the failed Plavix settlement continue at Bristol-Myers Squibb (BMS), with the apparently forced departure of CEO Peter Dolan and Senior Vice President and General Counsel Richard Willard on the recommendation of a federal monitor.
Researchers have new evidence that the use of some newer antidepressants, which belong to a class of drugs known as selective serotonin reuptake inhibitors or SSRIs, raises the risk of causing some people to become violent.